ID

39125

Beschreibung

A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic; ODM derived from: https://clinicaltrials.gov/show/NCT01462877

Link

https://clinicaltrials.gov/show/NCT01462877

Stichworte

Versionen (1)
  1. 03.12.19 03.12.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

3. Dezember 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Dyslipidemias NCT01462877

Englisch

Eligibility Dyslipidemias NCT01462877

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. ≥18 years and < 80 years, male or female
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
2. with at least one risk of coronary heart disease (chd) [medical history of myocardial infarction (mi) or coronary angiography shows coronary stenosis ≥ 50% or post percutaneous coronary intervention (pci) or post coronary artery bypass grafting (cabg)] or chd risk equivalents, which comprise,
Beschreibung

Risk Quantity Coronary heart disease | Myocardial Infarction | Coronary Stenosis Percentage Coronary angiography | Status post Percutaneous Coronary Intervention | Status post Coronary Artery Bypass Surgery | Coronary heart disease Risk Equivalent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0035647
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0010068
UMLS CUI [2]
C0027051
UMLS CUI [3,1]
C0242231
UMLS CUI [3,2]
C0439165
UMLS CUI [3,3]
C0085532
UMLS CUI [4,1]
C0231290
UMLS CUI [4,2]
C1532338
UMLS CUI [5,1]
C0231290
UMLS CUI [5,2]
C0010055
UMLS CUI [6,1]
C0010068
UMLS CUI [6,2]
C0035647
UMLS CUI [6,3]
C0205163
other clinical forms of atherosclerotic disease (ischemic stroke, peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease)
Beschreibung

Atherosclerosis | Ischemic stroke | Peripheral Arterial Disease | Aortic Aneurysm, Abdominal | Carotid Artery Disease Symptomatic

Datentyp

boolean

Alias
UMLS CUI [1]
C0004153
UMLS CUI [2]
C0948008
UMLS CUI [3]
C1704436
UMLS CUI [4]
C0162871
UMLS CUI [5,1]
C0007273
UMLS CUI [5,2]
C0231220
type 2 diabetes
Beschreibung

Diabetes Mellitus, Non-Insulin-Dependent

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
multiple risk factors that confer a 10-year risk for chd >20%.
Beschreibung

Risk factors multiple | Risk Percentage Coronary heart disease

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0035648
UMLS CUI [1,2]
C0439064
UMLS CUI [2,1]
C0035647
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C0010068
3. ≥ 2 months statin monotherapy with standard dose (atorvastatin ≤20mg q.d. or rosuvastatin ≤10mg q.d. or simvastatin ≤40mg q.d. or pravastatin ≤40mg q.d. or pitavastatin ≤4mg q.d or fluvastatin ≤80mg q.d. or lovastatin ≤40mg q.d.) and plan to continue the previous type and dose of statin
Beschreibung

Statins Standard dose | atorvastatin U/day | rosuvastatin U/day | Simvastatin U/day | Pravastatin U/day | pitavastatin U/day | fluvastatin U/day | Lovastatin U/day | Statins Dose Continue Planned

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0360714
UMLS CUI [1,2]
C1442989
UMLS CUI [1,3]
C0178602
UMLS CUI [2,1]
C0286651
UMLS CUI [2,2]
C0456683
UMLS CUI [3,1]
C0965129
UMLS CUI [3,2]
C0456683
UMLS CUI [4,1]
C0074554
UMLS CUI [4,2]
C0456683
UMLS CUI [5,1]
C0085542
UMLS CUI [5,2]
C0456683
UMLS CUI [6,1]
C1101838
UMLS CUI [6,2]
C0456683
UMLS CUI [7,1]
C0082608
UMLS CUI [7,2]
C0456683
UMLS CUI [8,1]
C0024027
UMLS CUI [8,2]
C0456683
UMLS CUI [9,1]
C0360714
UMLS CUI [9,2]
C0178602
UMLS CUI [9,3]
C0549178
UMLS CUI [9,4]
C1301732
4. triglycerides (tg)≥1.70 mmol/l (150mg/dl) and tg<5.65 mmol/l (500mg/dl)
Beschreibung

Triglycerides measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0202236
5. subject must be able to provide informed consent, approved by an independent ethics committee (iec)/institutional review board (irb), on his or her own behalf, prior to any study-specific procedures.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. hypersensitive to fenofibrate or to any of its excipients
Beschreibung

Fenofibrate allergy | Hypersensitivity Fenofibrate Excipient

Datentyp

boolean

Alias
UMLS CUI [1]
C0571869
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0033228
UMLS CUI [2,3]
C0015237
2. hepatic insufficiency [alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 2uln (upper limit of normal)]
Beschreibung

Hepatic Insufficiency | Alanine aminotransferase increased | Aspartate aminotransferase increased

Datentyp

boolean

Alias
UMLS CUI [1]
C1306571
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
3. renal insufficiency [creatinine clearance rate (ccr)<60ml/min estimated from cockcroft-gault equation ccr=(140-age)*weight(kg)*0.85(if female)/[0.818*cr (µmol/l)]
Beschreibung

Renal Insufficiency | Estimation of creatinine clearance by Cockcroft-Gault formula

Datentyp

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C2711451
4. creatine kinase (ck) > 2 uln
Beschreibung

Elevated creatine kinase

Datentyp

boolean

Alias
UMLS CUI [1]
C0151576
5. congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency
Beschreibung

Galactosemia Congenital | Glucose-galactose malabsorption | Lactase deficiency

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0016952
UMLS CUI [1,2]
C1744681
UMLS CUI [2]
C0268186
UMLS CUI [3]
C0302813
6. hypothyroidism
Beschreibung

Hypothyroidism

Datentyp

boolean

Alias
UMLS CUI [1]
C0020676
7. combination use of other non-statin lipid-regulating drugs such as fibrates, niacin and fish oil in previous 2 months
Beschreibung

Combined Modality Therapy | Hypolipidemic Agents | Exception Statins | Fibrates | Niacin | Fish Oil

Datentyp

boolean

Alias
UMLS CUI [1]
C0009429
UMLS CUI [2]
C0086440
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0360714
UMLS CUI [4]
C1449704
UMLS CUI [5]
C0027996
UMLS CUI [6]
C0016157
8. combination use of drug with similar structure as fenofibrate, especially ketoprofen
Beschreibung

Combined Modality Therapy | Pharmaceutical Preparations Fenofibrate Similar | Ketoprofen

Datentyp

boolean

Alias
UMLS CUI [1]
C0009429
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0033228
UMLS CUI [2,3]
C2348205
UMLS CUI [3]
C0022635
9. combination use of oral anticoagulants
Beschreibung

Combined Modality Therapy | Oral anticoagulants

Datentyp

boolean

Alias
UMLS CUI [1]
C0009429
UMLS CUI [2]
C0354604
10. pregnant or lactating woman
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
11. other conditions at investigator's discretion
Beschreibung

Condition Other

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0205394
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Dyslipidemias NCT01462877

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. ≥18 years and < 80 years, male or female
boolean
C0001779 (UMLS CUI [1])
Risk Quantity Coronary heart disease | Myocardial Infarction | Coronary Stenosis Percentage Coronary angiography | Status post Percutaneous Coronary Intervention | Status post Coronary Artery Bypass Surgery | Coronary heart disease Risk Equivalent
Item
2. with at least one risk of coronary heart disease (chd) [medical history of myocardial infarction (mi) or coronary angiography shows coronary stenosis ≥ 50% or post percutaneous coronary intervention (pci) or post coronary artery bypass grafting (cabg)] or chd risk equivalents, which comprise,
boolean
C0035647 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0010068 (UMLS CUI [1,3])
C0027051 (UMLS CUI [2])
C0242231 (UMLS CUI [3,1])
C0439165 (UMLS CUI [3,2])
C0085532 (UMLS CUI [3,3])
C0231290 (UMLS CUI [4,1])
C1532338 (UMLS CUI [4,2])
C0231290 (UMLS CUI [5,1])
C0010055 (UMLS CUI [5,2])
C0010068 (UMLS CUI [6,1])
C0035647 (UMLS CUI [6,2])
C0205163 (UMLS CUI [6,3])
Atherosclerosis | Ischemic stroke | Peripheral Arterial Disease | Aortic Aneurysm, Abdominal | Carotid Artery Disease Symptomatic
Item
other clinical forms of atherosclerotic disease (ischemic stroke, peripheral arterial disease, abdominal aortic aneurysm, and symptomatic carotid artery disease)
boolean
C0004153 (UMLS CUI [1])
C0948008 (UMLS CUI [2])
C1704436 (UMLS CUI [3])
C0162871 (UMLS CUI [4])
C0007273 (UMLS CUI [5,1])
C0231220 (UMLS CUI [5,2])
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Risk factors multiple | Risk Percentage Coronary heart disease
Item
multiple risk factors that confer a 10-year risk for chd >20%.
boolean
C0035648 (UMLS CUI [1,1])
C0439064 (UMLS CUI [1,2])
C0035647 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0010068 (UMLS CUI [2,3])
Statins Standard dose | atorvastatin U/day | rosuvastatin U/day | Simvastatin U/day | Pravastatin U/day | pitavastatin U/day | fluvastatin U/day | Lovastatin U/day | Statins Dose Continue Planned
Item
3. ≥ 2 months statin monotherapy with standard dose (atorvastatin ≤20mg q.d. or rosuvastatin ≤10mg q.d. or simvastatin ≤40mg q.d. or pravastatin ≤40mg q.d. or pitavastatin ≤4mg q.d or fluvastatin ≤80mg q.d. or lovastatin ≤40mg q.d.) and plan to continue the previous type and dose of statin
boolean
C0360714 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0286651 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0965129 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C0074554 (UMLS CUI [4,1])
C0456683 (UMLS CUI [4,2])
C0085542 (UMLS CUI [5,1])
C0456683 (UMLS CUI [5,2])
C1101838 (UMLS CUI [6,1])
C0456683 (UMLS CUI [6,2])
C0082608 (UMLS CUI [7,1])
C0456683 (UMLS CUI [7,2])
C0024027 (UMLS CUI [8,1])
C0456683 (UMLS CUI [8,2])
C0360714 (UMLS CUI [9,1])
C0178602 (UMLS CUI [9,2])
C0549178 (UMLS CUI [9,3])
C1301732 (UMLS CUI [9,4])
Triglycerides measurement
Item
4. triglycerides (tg)≥1.70 mmol/l (150mg/dl) and tg<5.65 mmol/l (500mg/dl)
boolean
C0202236 (UMLS CUI [1])
Informed Consent
Item
5. subject must be able to provide informed consent, approved by an independent ethics committee (iec)/institutional review board (irb), on his or her own behalf, prior to any study-specific procedures.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Fenofibrate allergy | Hypersensitivity Fenofibrate Excipient
Item
1. hypersensitive to fenofibrate or to any of its excipients
boolean
C0571869 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0033228 (UMLS CUI [2,2])
C0015237 (UMLS CUI [2,3])
Hepatic Insufficiency | Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
2. hepatic insufficiency [alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 2uln (upper limit of normal)]
boolean
C1306571 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
Renal Insufficiency | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
3. renal insufficiency [creatinine clearance rate (ccr)<60ml/min estimated from cockcroft-gault equation ccr=(140-age)*weight(kg)*0.85(if female)/[0.818*cr (µmol/l)]
boolean
C1565489 (UMLS CUI [1])
C2711451 (UMLS CUI [2])
Elevated creatine kinase
Item
4. creatine kinase (ck) > 2 uln
boolean
C0151576 (UMLS CUI [1])
Galactosemia Congenital | Glucose-galactose malabsorption | Lactase deficiency
Item
5. congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency
boolean
C0016952 (UMLS CUI [1,1])
C1744681 (UMLS CUI [1,2])
C0268186 (UMLS CUI [2])
C0302813 (UMLS CUI [3])
Hypothyroidism
Item
6. hypothyroidism
boolean
C0020676 (UMLS CUI [1])
Combined Modality Therapy | Hypolipidemic Agents | Exception Statins | Fibrates | Niacin | Fish Oil
Item
7. combination use of other non-statin lipid-regulating drugs such as fibrates, niacin and fish oil in previous 2 months
boolean
C0009429 (UMLS CUI [1])
C0086440 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0360714 (UMLS CUI [3,2])
C1449704 (UMLS CUI [4])
C0027996 (UMLS CUI [5])
C0016157 (UMLS CUI [6])
Combined Modality Therapy | Pharmaceutical Preparations Fenofibrate Similar | Ketoprofen
Item
8. combination use of drug with similar structure as fenofibrate, especially ketoprofen
boolean
C0009429 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0033228 (UMLS CUI [2,2])
C2348205 (UMLS CUI [2,3])
C0022635 (UMLS CUI [3])
Combined Modality Therapy | Oral anticoagulants
Item
9. combination use of oral anticoagulants
boolean
C0009429 (UMLS CUI [1])
C0354604 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
10. pregnant or lactating woman
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Condition Other
Item
11. other conditions at investigator's discretion
boolean
C0348080 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video